In resistant hypertension, amiloride was noninferior to spironolactone for reducing home SBP at 12 wk.

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III.

Aims: Congestive heart failure (CHF) is often coexisting in patients with atrial fibrillation (AF), but the clinical epidemiology of this association is still uncertain. We aimed to analyse characteristics, management, and outcomes of patients with and without CHF, in a real-world cohort of patients with AF.

Methods And Results: From the GLORIA-AF Registry Phase III, which enrolled adults with a recent diagnosis of AF and a CHA2DS2-VASc ≥ 1, we analysed factors associated with CHF at baseline, the association of CHF with use of oral anticoagulants (OAC) and other treatments, and the risk of adverse outcomes during a 3-year follow-up.

History of falls in patients with atrial fibrillation and risk of major outcomes: analysis from the Prospective GLORIA-AF Registry.

Falls pose concerns for the management and prognosis of patients with atrial fibrillation (AF). Epidemiological data on patients with AF who fall are limited. From the prospective global GLORIA-AF Registry Phase III study, we evaluated patients with a recent diagnosis of AF and CHADS-VASc score ≥ 1 according to previous history of falling at baseline.

Physical activity in patients with atrial fibrillation and adverse outcomes: results from a large-scale prospective multicenter European cohort.

Introduction And Objectives: Increased physical activity may improve outcomes in patients with atrial fibrillation (AF), but available data are limited. This study aimed to analyze the association between physical activity and major adverse outcomes in a large European AF cohort.

Methods: We used data from a prospective, observational, large-scale multicenter study of AF in European patients, involving 27 countries and 250 centers.

Atrial fibrillation and female sex: use of oral anticoagulants in a large European cohort and residual risk of thromboembolism and stroke.

Background: The role of female sex in stroke risk and oral anticoagulant (OAC) use in atrial fibrillation (AF) remains controversial. This study evaluates sex-specific differences in OAC prescription, residual risk of stroke/TIA and thromboembolism (STE), and the predictive performance of CHA₂DS₂-VASc vs. CHA₂DS₂-VA scores.

Clinical phenotype of anticoagulant discontinuation and the long-term prognosis in atrial fibrillation patients with high bleeding risk: A report from the GLORIA-AF registry.

Background: Discontinuation of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) at high risk of bleeding is commonly seen.

Objective: This study aimed to explore risk factors leading to OAC discontinuation and the impact on clinical events in patients with AF at high bleeding risk.

Methods: From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients With Atrial Fibrillation study, we analyzed, by OAC discontinuation, all-cause death, cardiovascular (CV) death, major adverse CV events (MACEs), thromboembolism (TE), major bleeding, stroke, and myocardial infarction during follow-up.

Distinct Platelet Phenotype and Reactivity in Individuals with Permanent Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Pilot Study.

Atrial fibrillation (AF) is linked to an elevated risk of thromboembolic events. Despite the use of guideline-recommended direct anticoagulants (DOACs), a significant proportion of AF patients show a residual risk of thromboembolic events, driven by mechanisms that are not fully understood.We conducted a pilot study to characterize the platelet function in DOACs-treated AF patients, to explore whether an association between platelets and the residual thromboembolic risk exists.

Adherence to the ABC (atrial fibrillation better care) pathway and risk of adverse outcomes in patients with chronic kidney disease: a report from the prospective APHRS-AF registry.

Background: Limited data exist on the effectiveness of the ABC (Atrial Fibrillation Better Care) pathway in reducing adverse events in Asian patients with atrial fibrillation (AF) and chronic kidney disease (CKD).

Methods: A post-hoc analysis of the prospective APHRS AF Registry. Patients were divided into CKD (eGFR < 60 ml/min) and non-CKD (eGFR ≥ 60 ml/min) groups.

Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III.

Background: Older age increases the risk of thromboembolism (TE) and major bleeding in atrial fibrillation (AF) patients, but limited evidence exists regarding the older population (age ≥ 80) especially from different global regions. Data on benefits of oral anticoagulants in these very old individuals are also limited.

Methods: From the prospective, multicenter Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation registry, we analysed by age all-cause death, cardiovascular death, major adverse cardiovascular events (MACE), TE, major bleeding, stroke, and myocardial infarction (MI) over 3-years follow-up.

Burnout among young Italian Internists: a cross-sectional study assessing prevalence and associated factors.

Burnout among physicians is associated with poor productivity at work, dissatisfaction, and regrets about career choices. The present study aims to evaluate the prevalence of burnout and its main associated factors among young Italian Internists. An online survey assessing different aspects of training and working conditions of young internists was conducted across European countries by the Young Internists Group of the European Federation of Internal Medicine (EFIM).

Neutrophil-lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry.

Background: Liver cirrhosis (LC) is a leading global cause of morbidity and mortality, with inflammation playing a key role in disease progression and clinical complications of LC. The Neutrophil/Lymphocyte Ratio (NLR), a readily available marker of systemic inflammation, has been linked to short-term adverse outcomes in LC, but data on long-term follow-up are limited. This study aimed to investigate the relationship between NLR and long-term all-cause mortality in an unselected cohort of LC patients.

Chronic kidney disease classification according to different formulas and impact on adverse outcomes in patients with atrial fibrillation: A report from a prospective observational European registry.

Background: Chronic kidney disease (CKD) and atrial fibrillation (AF) often coexist, making accurate renal function estimation crucial, typically through equations calculating estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl).

Objective: To compare the concordance and predictive performance of different renal function estimation equations in a European cohort of AF patients.

Methods: We analyzed data from AF patients enrolled in a prospective observational European registry.

Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry.

Aims: Whether the adoption of CHA2DS2-VA score, the sex-independent version of the CHA2DS2-VASc score is beneficial for stratifying risk of stroke in patients with atrial fibrillation (AF) remains controversial.

Methods And Results: Utilizing the data from the global, multicentre and prospective GLORIA-AF Registry Phase III, we compared the performances of CHA2DS2-VA and CHA2DS2-VASc scores in stratifying the risk of ischaemic stroke and thromboembolism (TE), and compared the risk of ischaemic stroke and TE, and the use of oral anticoagulants in male and female patients with AF. A total of 21 260 AF patients with available data were included in the analysis (mean age 70.

Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), encompasses a spectrum of liver diseases characterized by hepatic steatosis, the presence of at least one cardiometabolic risk factor, and no other apparent cause. Metabolic syndrome (MetS) is a cluster of clinical conditions associated with increased risk of cardiovascular disease, type 2 diabetes, and overall morbidity and mortality. This narrative review summarizes the changes in the management of people with MetS and NAFLD/MASLD from screening to therapeutic strategies that have occurred in the last decades.

In older adults with severe AS and complex CAD, PCI + TAVI vs. SAVR + CABG reduced patient-oriented outcomes at 1 y.

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Association of comorbidity patterns with outcomes and relation with the ABC pathway effectiveness in European patients with atrial fibrillation.

Background: Patients with atrial fibrillation (AF) show increasingly complex comorbidity profiles, with detrimental effects on prognosis.

Objective: The purpose of this study was to explore patterns of comorbidities in patients with AF.

Methods: From a European-wide prospective observational registry of AF patients, we performed a latent class analysis to identify patterns of comorbidities.

Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III.

Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF (< 3 months before baseline visit) were collected from the prospective Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry Phase III.

Atrial fibrillation versus atrial myopathy in thrombogenesis: Two sides of the same coin?

Atrial fibrillation (AF) and atrial myopathy are recognized contributors to cardiovascular morbidity, particularly ischemic stroke. AF poses an elevated risk of thrombogenesis due to irregular heart rhythm leading to blood stasis and clot formation. Atrial myopathy, marked by structural and functional alterations in the atria, is emerging as a crucial factor influencing thromboembolic events, independently of AF.

Patterns of pharmacological treatment in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF Registry Phase III.

Background: Polypharmacy (i.e., treatment with ≥ 5 drugs) is common in patients with atrial fibrillation (AF) and has been associated with suboptimal management and worse outcomes.